Piramal Pharma, 543635, PPLPHARMA Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

26,844.17
291.65
10

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

31,062.98
0.07%
3.27

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

-
-
7.60

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-
-
4.27

PAT CAGR (%)

10 Years
5 Years
3 Years

-
-
-63.81

P:E (Median)

8 Years
5 Years
3 Years

-
-
21.72

P:BV (Average)

8 Years
5 Years
3 Years

-
-
2.63

EV:EBITDA (Average)

8 Years
5 Years
3 Years

-
-
58.66

Earnings Forecasts:

(Updated: 06-06-2025)

Description 2024 2025 2026 2027
Adj EPS 0.14 0.69 1.77 4.87
P/E Ratio 1442.50 292.68 114.10 41.47
Revenue 8106 9151 9887 11658
EBITDA 1196 1445 1552 2185
Net Income 18 91 223 630
ROA 0.1 0.6
P/B Ratio 3.98 3.94 3.15 2.93
ROE 0.24 1.24 2.81 7.22
FCFF -147 -164 492 628
FCFF Yield -0.47 -0.52 1.57 2.01
Net Debt 4083 4335 4000 3723
BVPS 50.74 51.3 64.03 68.89

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var% Jun 24 Jun 23 Var%
Net Sales 1,689.80 1,525.30 10.78% 1,248.32 1,024.14 21.89% 1,284.39 994.24 29.18% 1,063.20 846.43 25.61%
Expenses 1,273.22 1,135.66 12.11% 1,028.98 898.61 14.51% 1,031.50 908.08 13.59% 911.57 829.84 9.85%
EBITDA 416.58 389.64 6.91% 219.34 125.53 74.73% 252.89 86.16 193.51% 151.63 16.59 813.98%
EBIDTM 24.65% 25.55% 17.57% 12.26% 19.69% 8.67% 14.26% 1.96%
Other Income 39.51 53.19 -25.72% 24.70 33.11 -25.40% 106.38 89.08 19.42% 36.76 26.68 37.78%
Interest 30.56 27.66 10.48% 29.17 17.42 67.45% 29.95 28.22 6.13% 24.88 33.80 -26.39%
Depreciation 61.17 52.50 16.51% 55.46 51.56 7.56% 53.61 50.83 5.47% 51.85 50.37 2.94%
PBT 364.36 362.67 0.47% 159.41 89.66 77.79% 275.71 96.19 186.63% 111.66 -40.90 -
Tax 87.09 89.59 -2.79% 40.61 15.32 165.08% 65.65 19.03 244.98% 26.39 -7.54 -
PAT 277.27 273.08 1.53% 118.80 74.34 59.81% 210.06 77.16 172.24% 85.27 -33.36 -
PATM 16.41% 17.90% 9.52% 7.26% 16.35% 7.76% 8.02% -3.94%
EPS 2.09 2.06 1.46% 0.90 0.56 60.71% 1.58 0.58 172.41% 0.64 -0.25 -

Description Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var% Jun 24 Jun 23 Var%
Net Sales 2,754.07 2,552.36 7.90% 2,204.22 1,958.57 12.54% 2,241.75 1,911.38 17.28% 1,951.14 1,748.85 11.57%
Expenses 2,193.08 2,022.43 8.44% 1,866.48 1,690.20 10.43% 1,900.14 1,645.74 15.46% 1,746.65 1,616.53 8.05%
EBITDA 560.99 529.93 5.86% 337.74 268.37 25.85% 341.61 265.64 28.60% 204.49 132.32 54.54%
EBIDTM 20.37% 20.76% 15.32% 13.70% 15.24% 13.90% 10.48% 7.57%
Other Income 42.03 26.38 59.33% 12.13 61.51 -80.28% 61.11 49.19 24.23% 19.54 38.31 -49.00%
Interest 103.68 114.22 -9.23% 103.31 105.88 -2.43% 107.64 109.87 -2.03% 106.96 118.52 -9.75%
Depreciation 242.76 196.13 23.78% 196.81 186.32 5.63% 192.22 184.51 4.18% 184.55 173.61 6.30%
PBT 256.58 215.44 19.10% 49.75 5.41 819.59% 102.86 20.45 402.98% -67.48 -121.50 -
Tax 119.30 126.21 -5.48% 63.12 9.25 582.38% 97.53 34.54 182.37% 43.56 -8.53 -
PAT 137.28 89.23 53.85% -13.37 -3.84 - 5.33 -14.09 - -111.04 -112.97 -
PATM 4.98% 3.50% -0.61% -0.20% 0.24% -0.74% -5.69% -6.46%
EPS 1.16 0.77 50.65% 0.03 0.08 -62.50% 0.17 0.04 325.00% -0.67 -0.81 -

Annual Results

Standalone Figures in Rs. Crores /

Consolidated

Description TTM Mar 24 Mar 23 Mar 22 Mar 21
Net Sales 5,285.71 4,390.11 3,443.22 3,340.42 2,938.81 Net Sales Growth 20.40% 27.50% 3.08% 13.67% Cost Of Goods Sold 2,245.96 2,108.84 1,768.48 1,561.51 1,227.77 Gross Profit 3,039.75 2,281.27 1,674.74 1,778.91 1,711.04 GP Margin 57.51% 51.96% 48.64% 53.25% 58.22% Total Expenditure 4,245.27 3,790.71 3,345.69 2,865.14 2,319.88 Power & Fuel Cost - 112.89 107.94 83.83 68.08 % Of Sales - 2.57% 3.13% 2.51% 2.32% Employee Cost - 613.93 548.50 448.03 395.15 % Of Sales - 13.98% 15.93% 13.41% 13.45% Manufacturing Exp. - 317.98 318.40 283.52 246.85 % Of Sales - 7.24% 9.25% 8.49% 8.40% General & Admin Exp. - 341.84 310.59 261.25 209.20 % Of Sales - 7.79% 9.02% 7.82% 7.12% Selling & Distn. Exp. - 212.89 230.60 182.88 135.62 % Of Sales - 4.85% 6.70% 5.47% 4.61% Miscellaneous Exp. - 82.34 61.18 44.12 37.21 % Of Sales - 1.88% 1.78% 1.32% 1.27% EBITDA 1,040.44 599.40 97.53 475.28 618.93 EBITDA Margin 19.68% 13.65% 2.83% 14.23% 21.06% Other Income 207.35 220.58 341.07 224.79 197.97 Interest 114.56 107.10 115.87 57.29 4.71 Depreciation 222.09 205.26 192.08 165.37 143.64 PBT 911.14 507.62 130.65 477.41 668.55 Tax 219.74 116.40 54.19 94.79 115.28 Tax Rate 24.12% 22.93% 43.81% 20.50% 16.79% PAT 691.40 391.22 69.50 367.54 571.50 PAT before Minority Interest 691.40 391.22 69.50 367.54 571.50 Minority Interest 0.00 0.00 0.00 0.00 0.00 PAT Margin 13.08% 8.91% 2.02% 11.00% 19.45% PAT Growth 76.73% 462.91% -81.09% -35.69% EPS 5.22 2.95 0.52 2.77 4.31

Description TTM Mar 24 Mar 23 Mar 22 Mar 21
Net Sales 9,151.18 8,171.16 7,081.55 6,559.10 6,314.90 Net Sales Growth 11.99% 15.39% 7.97% 3.87% Cost Of Goods Sold 3,231.65 2,954.00 2,703.30 2,451.26 2,059.11 Gross Profit 5,919.53 5,217.16 4,378.25 4,107.84 4,255.79 GP Margin 64.69% 63.85% 61.83% 62.63% 67.39% Total Expenditure 7,706.35 7,000.65 6,453.31 5,609.44 4,886.94 Power & Fuel Cost - 241.59 207.81 163.56 136.70 % Of Sales - 2.96% 2.93% 2.49% 2.16% Employee Cost - 2,029.50 1,896.35 1,588.83 1,467.74 % Of Sales - 24.84% 26.78% 24.22% 23.24% Manufacturing Exp. - 731.64 674.10 589.03 544.09 % Of Sales - 8.95% 9.52% 8.98% 8.62% General & Admin Exp. - 542.00 472.78 428.49 367.25 % Of Sales - 6.63% 6.68% 6.53% 5.82% Selling & Distn. Exp. - 359.75 372.59 317.81 247.91 % Of Sales - 4.40% 5.26% 4.85% 3.93% Miscellaneous Exp. - 142.17 126.38 70.46 64.14 % Of Sales - 1.74% 1.78% 1.07% 1.02% EBITDA 1,444.83 1,170.51 628.24 949.66 1,427.96 EBITDA Margin 15.79% 14.32% 8.87% 14.48% 22.61% Other Income 134.81 201.14 225.11 275.80 164.11 Interest 421.59 448.49 344.18 198.25 163.45 Depreciation 816.34 740.57 676.69 586.18 545.04 PBT 341.71 182.59 -167.52 441.03 883.58 Tax 323.51 161.47 66.31 109.02 114.02 Tax Rate 94.67% 134.78% -38.00% 25.59% 12.64% PAT 18.20 17.82 -186.46 375.96 835.03 PAT before Minority Interest 18.20 17.82 -186.46 375.96 835.03 Minority Interest 0.00 0.00 0.00 0.00 0.00 PAT Margin 0.20% 0.22% -2.63% 5.73% 13.22% PAT Growth 143.68% - - -54.98% EPS 0.14 0.13 -1.41 2.84 6.30

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 24 Mar 23 Mar 22 Mar 21
Shareholder's Funds 6,712.07 5,261.79 5,123.12 4,100.62 Share Capital 1,322.95 1,193.32 1,185.91 994.60 Total Reserves 5,361.65 4,068.47 3,937.21 3,105.92 Non-Current Liabilities 859.80 1,083.17 800.72 184.38 Secured Loans 363.94 592.34 477.12 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 Long Term Provisions 281.04 274.43 143.85 6.59 Current Liabilities 2,307.35 1,951.29 1,655.39 1,566.96 Trade Payables 1,107.71 761.67 646.80 584.12 Other Current Liabilities 503.64 430.07 488.22 681.78 Short Term Borrowings 531.64 720.34 390.21 165.20 Short Term Provisions 164.36 39.21 130.16 135.86 Total Liabilities 9,879.22 8,296.25 7,579.23 5,851.96 Net Block 2,612.16 2,601.87 2,438.98 1,626.81 Gross Block 3,774.93 3,564.57 3,225.28 2,260.11 Accumulated Depreciation 1,162.77 962.70 786.30 633.30 Non Current Assets 6,508.14 5,947.57 5,400.24 3,989.17 Capital Work in Progress 533.24 416.57 405.16 121.00 Non Current Investment 1,646.88 1,646.87 1,592.52 1,591.52 Long Term Loans & Adv. 1,715.86 1,282.22 963.54 649.84 Other Non Current Assets 0.00 0.04 0.04 0.00 Current Assets 3,371.08 2,348.68 2,178.99 1,862.79 Current Investments 61.28 100.12 37.01 0.00 Inventories 1,153.04 818.61 535.51 420.88 Sundry Debtors 1,331.38 909.56 989.22 839.75 Cash & Bank 241.73 64.16 137.23 152.35 Other Current Assets 583.65 28.98 39.00 44.50 Short Term Loans & Adv. 523.41 427.25 441.02 405.31 Net Current Assets 1,063.73 397.39 523.60 295.83 Total Assets 9,879.22 8,296.25 7,579.23 5,851.96

Description Mar 24 Mar 23 Mar 22 Mar 21
Shareholder's Funds 7,911.37 6,773.50 6,696.60 5,605.00 Share Capital 1,322.95 1,193.32 1,185.91 994.60 Total Reserves 6,560.95 5,580.18 5,510.69 4,610.30 Non-Current Liabilities 2,928.77 3,812.00 2,902.58 2,560.38 Secured Loans 2,483.75 3,383.54 2,622.14 2,339.16 Unsecured Loans 0.00 0.00 0.00 0.00 Long Term Provisions 316.45 275.97 145.34 6.78 Current Liabilities 4,457.10 3,851.04 3,118.01 2,590.70 Trade Payables 1,538.37 1,192.71 1,026.35 917.94 Other Current Liabilities 1,575.68 1,305.30 1,242.76 1,140.63 Short Term Borrowings 1,171.38 1,302.29 658.76 360.52 Short Term Provisions 171.67 50.74 190.14 171.61 Total Liabilities 15,297.24 14,436.54 12,717.19 10,756.08 Net Block 7,989.93 7,468.60 6,879.18 6,105.49 Gross Block 12,137.48 10,842.12 9,510.49 8,173.25 Accumulated Depreciation 4,147.55 3,373.52 2,631.31 2,067.76 Non Current Assets 9,744.97 9,593.07 8,565.30 7,006.96 Capital Work in Progress 1,115.80 1,418.58 1,172.34 626.65 Non Current Investment 240.26 211.87 216.77 122.67 Long Term Loans & Adv. 398.98 493.98 296.97 152.11 Other Non Current Assets 0.00 0.04 0.04 0.04 Current Assets 5,552.27 4,843.47 4,151.89 3,749.12 Current Investments 144.69 427.11 50.40 0.00 Inventories 2,175.88 1,681.37 1,388.80 1,232.00 Sundry Debtors 2,134.43 1,799.34 1,785.28 1,574.94 Cash & Bank 482.56 307.56 328.99 405.62 Other Current Assets 614.71 140.24 93.66 141.01 Short Term Loans & Adv. 532.78 487.85 504.76 395.55 Net Current Assets 1,095.17 992.43 1,033.88 1,158.42 Total Assets 15,297.24 14,436.54 12,717.19 10,756.08

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 24 Mar 23 Mar 22 Mar 21
Cash From Operating Activity 358.29 71.52 249.19 34.72 PBT 507.62 123.69 477.41 349.11 Adjustment 221.26 50.70 42.92 8.96 Changes in Working Capital -292.78 -42.84 -168.48 -228.06 Cash after chg. in Working capital 436.10 131.55 351.85 130.01 Interest Paid 0.00 0.00 0.00 0.00 Tax Paid -77.81 -60.03 -102.66 -95.29 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 Cash From Investing Activity -635.52 -435.05 -1,245.61 -4,382.89 Net Fixed Assets -327.03 -350.70 -1,249.33 Net Investments 38.83 -117.46 -38.01 Others -347.32 33.11 41.73 Cash from Financing Activity 451.38 290.12 896.40 4,494.16 Net Cash Inflow / Outflow 174.15 -73.41 -100.02 145.99 Opening Cash & Equivalents 54.28 127.69 146.72 0.74 Closing Cash & Equivalent 228.80 54.28 127.69 146.73

Description Mar 24 Mar 23 Mar 22 Mar 21
Cash From Operating Activity 1,004.54 483.89 766.42 597.58 PBT 119.80 -160.56 441.03 639.68 Adjustment 1,275.88 1,135.53 787.10 721.99 Changes in Working Capital -234.30 -302.08 -292.29 -619.58 Cash after chg. in Working capital 1,161.38 672.89 935.84 742.09 Interest Paid 0.00 0.00 0.00 0.00 Tax Paid -156.84 -189.00 -169.42 -144.51 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 Cash From Investing Activity -434.01 -1,338.78 -1,812.10 -4,479.93 Net Fixed Assets -327.03 -350.70 -1,249.33 Net Investments 38.83 -117.46 -38.01 Others -145.81 -870.62 -524.76 Cash from Financing Activity -422.36 817.79 794.19 3,976.83 Net Cash Inflow / Outflow 148.17 -37.10 -251.49 94.48 Opening Cash & Equivalents 53.23 85.18 261.97 151.95 Closing Cash & Equivalent 219.19 53.23 85.18 261.97

Financial Ratios

Standalone /

Consolidated

Description Mar 24 Mar 23 Mar 22 Mar 21
Book Value (Rs.) 50.53 43.06 42.19 41.23 ROA 4.30% 0.88% 5.47% 9.77% ROE 6.55% 1.34% 7.97% 13.94% ROCE 8.33% 3.64% 9.86% 16.21% Fixed Asset Turnover 1.25 1.05 1.24 1.30 Receivable days 88.86 96.97 98.40 104.30 Inventory Days 78.18 69.15 51.45 52.27 Payable days 161.78 145.35 143.86 173.65 Cash Conversion Cycle 5.26 20.77 5.99 -17.08 Total Debt/Equity 0.17 0.31 0.23 0.04 Interest Cover 5.74 2.07 9.07 146.81

Description Mar 24 Mar 23 Mar 22 Mar 21
Book Value (Rs.) 59.59 55.44 55.15 56.35 ROA 0.12% -1.37% 3.20% 7.76% ROE 0.24% -2.77% 6.11% 14.90% ROCE 5.07% 1.95% 7.10% 13.06% Fixed Asset Turnover 0.82 0.80 0.83 0.77 Receivable days 76.20 80.70 83.94 91.03 Inventory Days 74.72 69.11 65.47 71.21 Payable days 168.73 149.81 144.76 162.72 Cash Conversion Cycle -17.80 0.00 4.65 -0.47 Total Debt/Equity 0.58 0.81 0.60 0.52 Interest Cover 1.40 0.65 3.45 6.81

Top Investors:

ca alchemy investments

hdfc trustee company limited-hdfc flexi cap fund

east bridge capital master fund i ltd

indiahold limited

canara robeco mutual fund a/c canara robeco small cap fund

llp

investor education and protection fund (iepf)

Annual Reports:

FY 2024

FY 2023

FY 2022

News Update:

USFDA concludes GMP inspection at Piramal Pharma’s Canada facility
2nd Jun 2025, 15:14 PM

The inspection was completed successfully with Zero Form - 483 observations
Read More
Piramal Pharma reports 51.57% rise in Q4 consolidated net profit
15th May 2025, 12:30 PM

The total consolidated income of the company increased by 8.43% at Rs 2,796.10 crore for Q4FY25
Read More
Piramal Pharma receives EIR from USFDA for Turbhe facility
12th May 2025, 12:12 PM

The company has received the EIR for its Turbhe facility
Read More
Piramal Pharma’s arm inks pact with PPL Pharma
24th Apr 2025, 12:38 PM

The Transaction is expected to be completed within a period of around 6 months approximately
Read More
Piramal Finance partners with ICICI Bank
10th Apr 2025, 15:22 PM

Through this partnership, the company combines its innovative ‘High Tech + High Touch’ approach with the financial and banking expertise of ICICI Bank
Read More
Piramal Pharma commences commercial production of Sevoflurane at Telangana facility
2nd Apr 2025, 17:51 PM

This would boost the company’s capability to also tap into inhalation anesthesia opportunities in the ROW markets in addition to the USA markets
Read More
Piramal Pharma’s arm, BPCO get UKMHRA approval for Neoatricon in UK
21st Mar 2025, 10:46 AM

PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
Read More

Piramal Pharma Ltd.

Pharmaceuticals & Drugs

BSE: 543635 | NSE: PPLPHARMA

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores /

Results Balance Sheet

Standalone Figures in Rs. Crores /

Cash Flow

Standalone Figures in Rs. Crores /

Financial Ratios

Standalone /

Top Investors:

Annual Reports:

News Update:

Piramal Pharma Ltd.

Pharmaceuticals & Drugs

BSE: 543635 | NSE: PPLPHARMA

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores /

Results Balance Sheet

Standalone Figures in Rs. Crores /

Cash Flow

Standalone Figures in Rs. Crores /

Financial Ratios

Standalone /

Top Investors:

Annual Reports:

News Update: